Download PDF
Thromb Haemost 1991; 65(04): 377-381
DOI: 10.1055/s-0038-1648156
Original Article
Schattauer GmbH Stuttgart

Antithrombotic Activity of a Novel C-Terminal Hirudin Analog in Experimental Animals

R J Broersma
Merrell Dow Research Institute, Indianapolis, IN, USA
,
L W Kutcher
Merrell Dow Research Institute, Indianapolis, IN, USA
,
E F Heminger
Merrell Dow Research Institute, Indianapolis, IN, USA
,
J L Krstenansky
*   Merrell Dow Research Institute, Cincinnati, OH, USA
,
F N Marshall
Merrell Dow Research Institute, Indianapolis, IN, USA
› Author Affiliations
Further Information

Publication History

Received: 13 July 1989

Accepted after revision 11 December 1990

Publication Date:
02 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

A synthetic hirudinsgs55-65 C-terminal fragment analog was evaluated for anticoagulant activity and in models of experimental thrombosis in mice and rats. Intravenous injection caused doserelated inhibition of thrombin and anticoagulation in rat blood samples, protection from thromboembolism in mice and inhibition of stasis-induced venous thrombosis in rats. Antithrombotic effectiveness corresponded with anticoagulant activity. Anephric animals exhibited longer duration of activity than normal animals suggesting the kidney as a major route of elimination.

 

  • References

  • 1 Hauptmann J, Kaiser B, Markwardt R, Nowak G. Anticoagulant and antithrombotic action of novel specific inhibitors of thrombin. Thromb Haemostas 1980; 43: 118-123
    PubMedGoogle Scholar
  • 2 Kaiser B, Markwardt F. Experimental studies on the antithrombotic action of a highly effective synthetic thrombin inhibitor. Thromb Haemostas 1986; 55: 194-196
    PubMedGoogle Scholar
  • 3 Markwardt I, Nowak G, Hoffman J. Comparative studies on thrombin inhibitors in experimental microthrombosis. Thromb Haemostas 1983; 49: 235-237
    PubMedGoogle Scholar
  • 4 Stone SR, Hofsteenge J. Kinetics of the inhibition of thrombin by hirudin. Biochemistry 1986; 25: 4622-4628
    CrossrefPubMedGoogle Scholar
  • 5 Markwardt R, Hauptman J, Nowak G, Klessen Ch, Walsmann p. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemostas 1982; 47: 226-229
    PubMedGoogle Scholar
  • 6 Krstenansky JL, Mao SJT. Antithrombin properties of C-terminus of hirudin using synthetic unsulfated Nth-acetyl-hirudinls os. FEBS Lett 1987; 211: 10-16
    CrossrefPubMedGoogle Scholar
  • 7 Krstenansky JL, Mao SJT. Comparison of hirudin and hirudin PA Cterminal fragments and related analogs as antithrombin agents. Thromb Res 1988; 52: 137-141
    CrossrefPubMedGoogle Scholar
  • 8 Krstenansky JL, Broersma RI, owen J, payne MH, yates MT, Mao SJT. Development of MDL 28,050, a small stable anticoagulant based on a functional domain of the leech antithrombin, hirudin. Thromb Haemostas 1990; 63: 208-214
    PubMedGoogle Scholar
  • 9 Dodt J, Muller H-P, Seemuller y, Chang J-y. The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS Lett 1984; 165: 180-184
    CrossrefPubMedGoogle Scholar
  • 10 Wessler S, Reimer SM, Sheps MC. Biologic assay of a thrombosisinducing activity in human serum. J Appl physiol 1959; 14: 943-946
    CrossrefPubMedGoogle Scholar
  • 11 Nowak G, Markwardt E. Pharmacokinetic studies with hirudin. Thromb Res 1987; Suppl VII 45-36
    PubMedGoogle Scholar
  • 12 Henschen A, Markwardt R, Walsmann P. Identification by HPLC analysis of the unaltered forms of hirudin and desulfated hirudin after kidney passage. Thromb Res 1987; Suppl VII 45-37
    PubMedGoogle Scholar